Chief executive, Fresenius SE & Co. KGaA
Appears in 1 story
Leading #FutureFresenius strategy
Fresenius now owns 100% of mAbxience. On September 30, the German healthcare group bought the remaining 45% from Insud Pharma for up to €750 million, completing a structure it started in August 2022.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
